Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/2772
Title: Sodium bicarbonate for metabolic acidosis in the ICU: Results of a pilot randomized double-blind clinical trial.
Author: Neto, A.
Fujii, T.
McNamara, M.
Moore, J.
Young, P.
Peake, S.
Bailey, M.
Hodgson, C.
Higgins A.
See, E.
Secombe, P.
Cambpell, L.
Young, M.
Maeda, M.
Pilcher, D.
Nichol, A.
Deane, A.
Licari, E.
White, K.
French, C.
Shehabi, Y.
Cross, A.
Maiden, M.
Kadam, U.
El Khawas, Khaled
Cooper, J.
Bellomo, R.
Udy, A.
Issue Date: 2024
Publication Title: Critical Care Medicine
Volume: 51
Issue: 11
Start Page: e221
Abstract: OBJECTIVES: To identify the best population, design of the intervention, and to assess between-group biochemical separation, in preparation for a future phase III trial. DESIGN: Investigator-initiated, parallel-group, pilot randomized double-blind trial. SETTING: Eight ICUs in Australia, New Zealand, and Japan, with participants recruited from April 2021 to August 2022. PATIENTS: Thirty patients greater than or equal to 18 years, within 48 hours of admission to the ICU, receiving a vasopressor, and with metabolic acidosis (pH < 7.30, base excess [BE] < –4 mEq/L, and Paco2 < 45 mm Hg). INTERVENTIONS: Sodium bicarbonate or placebo (5% dextrose). MEASUREMENTS AND MAIN RESULT: The primary feasibility aim was to assess eligibility, recruitment rate, protocol compliance, and acid–base group separation. The primary clinical outcome was the number of hours alive and free of vasopressors on day 7. The recruitment rate and the enrollment-to-screening ratio were 1.9 patients per month and 0.13 patients, respectively. Time until BE correction (median difference, –45.86 [95% CI, –63.11 to –28.61] hr; p < 0.001) and pH correction (median difference, –10.69 [95% CI, –19.16 to –2.22] hr; p = 0.020) were shorter in the sodium bicarbonate group, and mean bicarbonate levels in the first 24 hours were higher (median difference, 6.50 [95% CI, 4.18 to 8.82] mmol/L; p < 0.001). Seven days after randomization, patients in the sodium bicarbonate and placebo group had a median of 132.2 (85.6–139.1) and 97.1 (69.3–132.4) hours alive and free of vasopressor, respectively (median difference, 35.07 [95% CI, –9.14 to 79.28]; p = 0.131). Recurrence of metabolic acidosis in the first 7 days of follow-up was lower in the sodium bicarbonate group (3 [20.0%] vs. 15 [100.0%]; p < 0.001). No adverse events were reported. CONCLUSIONS: The findings confirm the feasibility of a larger phase III sodium bicarbonate trial; eligibility criteria may require modification to facilitate recruitment.
URI: http://hdl.handle.net/11054/2772
DOI: https://doi.org/10.1097/CCM.0000000000005955
Internal ID Number: 02739
Health Subject: INTENSIVE CARE
ICU
METABOLIC ACIDOSIS
SODIUM BICARBONATE
Type: Journal Article
Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.